ImageneBio (IMA) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company focused on therapeutics for immunological, autoimmune, and inflammatory diseases.

• Lead asset, IMG-007 (olevaprubart), is a non-depleting anti-OX40 monoclonal antibody targeting activated T cells, initially for atopic dermatitis and alopecia areata.

• Pipeline potential for additional indications such as asthma, rheumatoid arthritis, and hidradenitis suppurativa.

• Resulted from a merger between Ikena Oncology and Inmagene Biopharmaceuticals, with a 1-for-12 reverse stock split and subsequent name change to ImageneBio, Inc.

• Principal executive offices in San Diego, CA; common stock trades on Nasdaq under the symbol "IMA."

Financial performance and metrics

• As of August 4, 2026, aggregate market value of common stock held by non-affiliates was approximately $51.1 million, based on 8,370,413 shares at $6.11 per share.

• No revenue from product sales and operating losses since inception, as noted in the auditor's report.

Use of proceeds and capital allocation

• Net proceeds from securities sales intended for general corporate purposes, including clinical trial and R&D expenses, working capital, and administrative expenses.

• Pending use, proceeds will be invested in short- and intermediate-term, interest-bearing obligations or investment-grade instruments.